Novel anti-VEGF agent supplies further get advantages when mixed with ranibizumab for vascular age-related macular degeneration

1. In a segment II randomized trial, intravitreal injection with each ranibizumab and OPT-302, a VEGF-C and -D inhibitor, led to larger development in visible acuity at 24 weeks than ranibizumab on my own in sufferers with degeneration Age-related macular degeneration. (AMD). 2. OPT-302 was once now not related to an larger chance of inauspicious … Read more